PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
Tel Aviv, Israel – August 20, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company’s proprietary post-surgical pain formulation. The study, which has now completed […]
PainReform Provides Business Update for the Second Quarter of 2024
Reaches full enrollment in the second part of Phase 3clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late 2024 New highly scalable manufacturing process expectedto significantly enhance future commercialization efforts Tel Aviv, Israel – August 15, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical […]
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects
New formulations designed to enhance postoperative recovery Tel Aviv, Israel – August 12 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. These novel […]
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
Tel Aviv, Israel – August 7, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110’s […]
PainReform Ltd. Announces Favorable Wound Healing Datain Human Clinical Trials for PRF-110
PRF-110 promoted normal wound healing and preventedscar formation following surgical procedures Company reaffirms it is on track to report top-line resultsfrom the Phase 3 trial in the second half of 2024 Tel Aviv, Israel – August 5, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the […]
PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
New process expected to significantly bolster future commercialization efforts Tel Aviv, Israel – August 1, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company’s new highly scalable manufacturing […]
PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing
Tel Aviv, Israel – July 24, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has filed a patent covering its new and highly scalable manufacturing process for PRF-110, its flagship product designed to revolutionize post-operative pain control. The […]
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110
Tel Aviv, Israel – June 26, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major milestone on the way to registration – the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel […]
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
Tel Aviv, Israel – May 31, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid […]
PainReform Provides Business Update for the First Quarter of 2024
Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 Tel Aviv, Israel – May 15, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2024. Ilan Hadar, Chief Executive Officer of PainReform, […]
